Clinical Trial Update: Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes [NA]

View source ↗

Summary

A clinical trial evaluating the safety and effects of autologous adipose-derived stromal cells delivered to patients with Type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Autologous adipose-derived stromal cells (adipose-derived stromal cells)

Snippet

Sponsor: Ageless Regenerative Institute | Conditions: Diabetes Mellitus Type II | NA | Status: WITHDRAWN